CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Participate in financial planning workshops tailored for young adults. Gain the skills needed to secure your financial future.
17,930 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
When the government backs quantum startups with significant funding, investors wonder which stocks stand to gain. Thi...
A regulatory milestone sparked a notable move for Oklo shares, highlighting how news on licensing can lift niche ener...
Mortgage rates 6.5% can slow momentum, but they don’t stop your investing goals. This guide delivers six practical mo...
A director quietly sold a notable stake in American Superconductor, prompting questions about what it signals for inv...
New York will distribute $2.1 billion in STAR property tax relief to nearly 2.8 million homeowners this summer and fa...
A new Harvard study shows the income needed to afford median-priced homes has nearly doubled since 2020, highlighting...
When Intuitive Machines announced a major equity raise, the stock sold off hard. But a disciplined look shows the mov...
Investors are buzzing about SpaceX going public and what the first earnings report might reveal. Here are four core a...
Two very different corners of the consumer space compete for attention in 2026: fashion-forward American Eagle Outfit...
Apple hikes prices on Macs and iPads amid a sharp rise in memory chip costs driven by AI infrastructure demand. The m...
Iran launched drone and missile strikes against Bahrain and Kuwait, raising fears that peace talks could collapse. Ma...